ALNY   $273.89  -0.93% Market Closed After Close 273.88 -0.00%

Alnylam Pharmaceuticals Inc
Total Cash 2.62B
totalCashPerShare 20.444
EBITDA 157.97M
Total Debt 2.71B
quickRatio 2.781
currentRatio 3.007
Total Revenue 2.34B
debtToEquity
Revenue/Share 18.617
ROA 0.01731
ROE
grossProfits
freeCashflow 424.34M
operatingCashflow 372.26M
earningsGrowth
revenueGrowth 1.07
grossMargins 0.86998004
ebitdaMargins 0.067379996
operatingMargins 0.07368
profitMargins -0.03111
enterpriseValue 34.14B
forwardPE -173.37907
floatShares 127.84M
sharesOutstanding 128.38M
sharesShort 3.77M
sharesShortPriorMonth 4.33M
dateShortInterest
sharesPercentSharesOut 0.03%
heldPercentInsiders 0.00%
heldPercentInstitutions 0.96%
Short Ratio help_outline 3.64%
shortPercentOfFloat 0.03%
impliedSharesOutstanding
bookValue -0.024
Price To Book help_outline
earningsQuarterlyGrowth
netIncomeToCommon -72.94M
trailingEps -0.56%
forwardEps -1.53%
enterpriseToEbitda 216.11
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.97 3Q 2024
institutionsCount 829
lastUpdated Sept. 16, 2024, 12:23 p.m.